(NASDAQ: LVTX) Lava Therapeutics Nv's forecast annual revenue growth rate of -18.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Lava Therapeutics Nv's revenue in 2024 is $7,357,608.On average, 1 Wall Street analysts forecast LVTX's revenue for 2024 to be $184,023,609, with the lowest LVTX revenue forecast at $184,023,609, and the highest LVTX revenue forecast at $184,023,609. On average, 2 Wall Street analysts forecast LVTX's revenue for 2027 to be $118,695,228, with the lowest LVTX revenue forecast at $103,316,112, and the highest LVTX revenue forecast at $134,074,344.
In 2028, LVTX is forecast to generate $954,188,702 in revenue, with the lowest revenue forecast at $685,093,607 and the highest revenue forecast at $1,480,864,271.